1. Home
  2. MDWD vs TG Comparison

MDWD vs TG Comparison

Compare MDWD & TG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • TG
  • Stock Information
  • Founded
  • MDWD 2000
  • TG 1988
  • Country
  • MDWD Israel
  • TG United States
  • Employees
  • MDWD N/A
  • TG N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • TG Metal Fabrications
  • Sector
  • MDWD Health Care
  • TG Industrials
  • Exchange
  • MDWD Nasdaq
  • TG Nasdaq
  • Market Cap
  • MDWD 208.2M
  • TG 301.0M
  • IPO Year
  • MDWD 2014
  • TG 1989
  • Fundamental
  • Price
  • MDWD $19.34
  • TG $9.30
  • Analyst Decision
  • MDWD Strong Buy
  • TG
  • Analyst Count
  • MDWD 2
  • TG 0
  • Target Price
  • MDWD $35.00
  • TG N/A
  • AVG Volume (30 Days)
  • MDWD 48.9K
  • TG 79.6K
  • Earning Date
  • MDWD 08-13-2025
  • TG 08-06-2025
  • Dividend Yield
  • MDWD N/A
  • TG N/A
  • EPS Growth
  • MDWD N/A
  • TG N/A
  • EPS
  • MDWD N/A
  • TG N/A
  • Revenue
  • MDWD $19,213,000.00
  • TG $617,839,000.00
  • Revenue This Year
  • MDWD $20.80
  • TG N/A
  • Revenue Next Year
  • MDWD $26.92
  • TG N/A
  • P/E Ratio
  • MDWD N/A
  • TG N/A
  • Revenue Growth
  • MDWD N/A
  • TG 17.42
  • 52 Week Low
  • MDWD $14.14
  • TG $4.58
  • 52 Week High
  • MDWD $24.00
  • TG $9.43
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 40.24
  • TG 66.70
  • Support Level
  • MDWD $18.97
  • TG $8.67
  • Resistance Level
  • MDWD $19.87
  • TG $8.98
  • Average True Range (ATR)
  • MDWD 0.57
  • TG 0.26
  • MACD
  • MDWD -0.17
  • TG 0.04
  • Stochastic Oscillator
  • MDWD 25.31
  • TG 86.73

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About TG Tredegar Corporation

Tredegar Corp, through its subsidiaries, engages in the manufacture of polyethylene plastic films, polyester films, and aluminum extrusions. Polyethylene plastic films produce plastic films, elastics, and laminate materials that are used in personal care products, surface protection films, and specialty and optical lighting applications. The company operates through segments including PE films, flexible packaging films, and aluminum extrusions. Aluminum extrusions generate the majority of revenue and provide high-quality, soft-alloy, medium-strength aluminum utilized in the building and construction, automotive, consumer durables, machinery and equipment, electrical, and distribution markets. Revenue is generated from the United States, Asia, and Brazil.

Share on Social Networks: